@article{d993058475fc4f248a513ff9385e9ec9,
title = "Schizophrenia and substance use comorbidity: A genome-wide perspective",
abstract = "Dual diagnosis with substance use disorders (SUDs) consistently contributes to the premature mortality and increased disability observed in schizophrenia. Large genome-wide association studies are providing the information needed to investigate the genetic architecture of psychiatric disorders. Here, we discuss recent genetic investigations of dual diagnosis (i.e., schizophrenia plus a SUD) and how these findings can inform public health messages.",
author = "Renato Polimanti and Arpana Agrawal and Joel Gelernter",
note = "Funding Information: The authors{\textquoteright} research is supported by grants from the US National Institutes of Health (R01 DA12690, R01 AA017535, P50 AA012870, U01 MH109532, R21 AA024404 and K02DA32573), the VA Connecticut Mental Illness Research Education and Clinical Center (MIRECC), and a National Alliance for Research on Schizophrenia and Depression (NARSAD) Young Investigator Award from the Brain \& Behavior Research Foundation. Publisher Copyright: {\textcopyright} 2017 The Author(s).",
year = "2017",
month = mar,
day = "21",
doi = "10.1186/s13073-017-0423-3",
language = "English",
volume = "9",
journal = "Genome medicine",
issn = "1756-994X",
number = "1",
}